Oral lesions after infection by SARS CoV 2: two case reports.
Palavras-chave:
SARS-CoV-2, Oral manifestations, Oral ulcer, Pemphigus, Mouth, Mucous membraneResumo
Introduction: The SARS CoV 2 infection has resulted in several health, economic, and social crises in all areas. The disease shows a substantial biological diversity in humans causing a series of sequels in the trans- or post-infection period in the entire organism.
Case Report: The manifestations that occur in the oral cavity and pharynx have not been evaluated. In this study, two clinical cases are reported. The first patient, a 67-year-old male, presents erosive lesions on the dorsal surface of his tongue after SARS CoV 2 infection.
Results: Therapy consisting of reinforcing oral cleaning, use of antifungal solutions, mouthwashes containing superoxidation solution and B complex was given to the patient. The reported lesions improved satisfactorily. The second case, a 47-year-old male patient, presented vesiculobullous lesions on the lingual and labial mucosa accompanied by severe painful symptoms after SARS CoV 2 infection. An incisional biopsy was performed. The histopathological result was compatible with pemphigus vulgaris, and the treatment protocol was started with 0.1% topical mometasone and 2g miconazole gel, observing adequate involution of the lesions after 20 days.
Conclusions: The aim of this study is to report on the lesions affecting the oral cavity and pharynx in post-COVID patients with the aim of carrying out a thorough intraoral examination, establishing a clinical or histopathological diagnosis to implement a specific treatment plan in each case to improve the health and quality of life of the patients.
Downloads
Referências
[1]. Nejabi MB, Noor NAS, Raufi N, Essar MY, Ehsan E, Shah J, Shah A, Nemat A. Tongue ulcer in a patient with COVID-19: a case presentation. BMC Oral Health. 2021 May 20;21(1):273. doi: 10.1186/s12903-021-01635-8. PMID: 34016110; PMCID: PMC8135170. https://doi.org/10.1186/s12903-021-01635-8
[2]. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020 Apr;92(4):418-423. https://doi.org/10.1002/jmv.25681. Epub 2020 Feb 7. Erratum in: J Med Virol. 2020;92(10):2249. PMID: 31967327; PMCID: PMC7167049.
[3]. Koka V, Huang XR, Chung ACK, Wang W, Truong LD, Lan HY. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. Am J Pathol. 2008;172(5):1174–83. https://pubmed.ncbi.nlm.nih.gov/18403595/
[4]. Xu, H., Zhong, L., Deng, J. et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 12, 8 (2020). https://doi.org/10.1038/s41368-020-0074-x
[5]. Brandão TB, Gueiros LA, Melo TS, Prado-Ribeiro AC, Nesrallah ACFA, Prado GVB, Santos-Silva AR, Migliorati CA. Oral lesions in patients with SARS-CoV-2 infection: could the oral cavity be a target organ? Oral Surg Oral Med Oral Pathol Oral Radiol. 2021;131(2):e45-e51. https://doi.org/10.1016/j.oooo.2020.07.014. Epub 2020 Aug 18. PMID: 32888876; PMCID: PMC7434495.
[6]. Díaz Rodríguez M, Jimenez Romera A, Villarroel M. Oral manifestations associated with COVID-19. Oral Dis. 2020;(odi.13555). https://doi.org/10.1111/odi.1 3555
[7]. Ansari R, Gheitani M, Heidari F, Heidari F. Oral cavity lesions as a manifestation of the novel virus (COVID-19). Oral Dis. 2021;27 Suppl 3:771-772. https://doi.org/10.1111/odi.13465. Epub 2020 Jul 10. PMID: 32510821.
[8]. Eghbali Zarch R, Hosseinzadeh P. COVID-19 from the perspective of dentists: A case report and brief review of more than 170 cases. Dermatol Ther. 2021;34(1):e14717. -https://doi.org/10.1111/dth.14717. Epub 2021 Jan 1. PMID: 33368888; PMCID: PMC7883121.
[9]. Ciccarese G, Drago F, Boatti M, Porro A, Muzic SI, Parodi A. Oral erosions and petechiae during SARS-CoV-2 infection. J Med Virol. 2021;93(1):129–32. https://doi.org/10.1002/jmv.26221
[10]. Hanna R, Dalvi S, Benedicenti S, Amaroli A, S?l?gean T, Pop ID, Todea D, Bordea IR. Photobiomodulation Therapy in Oral Mucositis and Potentially Malignant Oral Lesions: A Therapy Towards the Future. Cancers (Basel). 2020;12(7):1949. https://doi.org/10.3390/cancers12071949. PMID: 32708390; PMCID: PMC 7409159.
[11]. Cebeci Kahraman F, Ça?kurlu H. Mucosal involvement in a COVID-19-positive patient: A case report. Dermatol Ther. 2020;33(4):e13797. https://doi.org/10.1111/dth.13797. Epub 2020 Jul 3. PMID: 32520428; PMCID: PMC7300528.
[12]. Martín Carreras-Presas C, Amaro Sánchez J, López-Sánchez AF, Jané-Salas E, Somacarrera Pérez ML. Oral vesiculobullous lesions associated with SARS-CoV-2 infection. Oral Dis. 2021;27 Suppl 3(Suppl 3):710-712. https://doi.org/10.1111/odi.13382. Epub 2020 May 29. PMID: 32369674; PMCID: PMC7267423.
[13]. Soares CD, Carvalho RA, Carvalho KA, Carvalho MG, Almeida OP. Letter to Editor: Oral lesions in a patient with Covid-19. Med Oral Patol Oral Cir Bucal. 2020;25(4):e563-e564. https://doi.org/ 10.4317/medoral.24044. PMID: 32520921; PMCID: PMC 7338069.
[14]. Sinadinos A, Shelswell J. Oral ulceration and blistering in patients with COVID-19. Evid Based Dent. 2020;21(2):49. https://doi.org/10.1038/s41432-020-0100-z. PMID: 32591655; PMCID: PMC7317274.
[15]. Bardellini E, Veneri F, Amadori F, Conti G, Majorana A. Photobiomodulation therapy for the management of recurrent aphthous stomatitis in children: clinical effectiveness and parental satisfaction. Med Oral Patol Oral Cir Bucal. 2020;25(4):e549-e553. https://doi.org/10.4317/medoral.23573. PMID: 32388522; PMCID: PMC7338059. https://pubmed.ncbi.nlm.nih.gov/32 388522/
[16]. Silva LN, de Mello TP, de Souza Ramos L, Branquinha MH, Roudbary M, Dos Santos ALS. Fungal Infections in COVID-19-Positive Patients: A Lack of Optimal Treatment Options. Curr Top Med Chem. 2020;20(22):1951-1957. https://doi.org/10.2174/156802662022200917110102. PMID: 33040728. https://pubmed.ncbi.nlm.nih.gov/33040728/
Publicado
Como Citar
Edição
Seção
Copyright (c) 2023 Universidad de Concepción
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
Este trabalho está licensiado sob uma licença Creative Commons Attribution 4.0 International License.
Este es una Revista de acceso abierto distribuido bajo los términos de Creative Commons Attribution License (CC BY 4.0). Se permite el uso, distribución o reproducción en otros foros, siempre que se acredite al autor o autores originales y a los propietarios de los derechos de autor y se cite la publicación original en esta revista, de acuerdo con la práctica académica aceptada. No se permite ningún uso, distribución o reproducción que no cumpla con estos términos. © 2023.